Abstract
PURPOSE: R667 is an orally active, gamma selective, retinoid receptor agonist. In contrast to to all trans retinoic acid ATRA, a potent pan agonist agonist with no retinoid receptor selectivity and a different PK profile, R667 showed improved efficacy in promoting structural lung repair and functional improvement in animal models of emphysema with fewer side effects. Two clinical studies are now extending that evaluation as a potential treatment for human emphysema.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
